Vascular-homing peptides for cancer therapy - 01/07/17


pages | 9 |
Iconographies | 1 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | The heterogeneous feature of tumor vasculature allows the identification of novel vascular-homing peptides by the in vivo phage display. |
• | Recent progress in clinical studies evaluating RGD and NGR peptides are reported. |
• | Advances in preclinical research for newly emerged novel vascular-homing peptides are discussed. |
Abstract |
In the past 30 years, a variety of phage libraries have been extensively utilized to identify and develop tumor homing peptides (THPs). THPs specifically bind to tumor cells or elements of the tumor microenvironment while no or low affinity to normal cells. In this regard, the efficacy of therapeutic agents in cancer therapy can be enhanced by targeting strategies based on coupling with THPs that recognize receptors expressed by tumor cells or tumor vasculature. Especially, vascular-homing peptides, targeting tumor vasculature, have their receptors expressed on or around the blood vessel including pro-angiogenic factors, metalloproteinase, integrins, fibrin–fibronectin complexes, etc. This review briefly summarizes recent studies on identification and therapeutic applications of vascular-homing peptides targeting common angiogenic markers or with unknown vascular targets in some certain types of cancers. These newly discovered vascular-homing peptides are promising candidates which could provide novel strategies for cancer therapy.
Le texte complet de cet article est disponible en PDF.Keywords : Vascular- targeting therapy, Tumor homing peptides, Anti-cancer therapy
Plan
Vol 92
P. 187-195 - août 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?